The sector’s diagnostics focus intensified with additional evidence that molecular assays are being broadened across the cancer care continuum. Personalis’ Medicare expansion for NeXT Personal in the neoadjuvant setting complements Guardant’s upgraded CDx approval that supports wider tumor profiling for treatment decisions. From an operational standpoint, both updates are designed around real-world clinical workflows: blood draws for rapid genomic readouts and MRD measurement to track response and guide therapy timing. For biotech developers and clinical labs, these decisions indicate expanding payer and regulatory comfort with assay upgrades as evidence packages mature.